Venture Visionary Partners LLC Purchases 10,231 Shares of Bristol-Myers Squibb (NYSE:BMY)

Venture Visionary Partners LLC increased its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 10.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 107,367 shares of the biopharmaceutical company's stock after purchasing an additional 10,231 shares during the quarter. Venture Visionary Partners LLC's holdings in Bristol-Myers Squibb were worth $5,555,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in BMY. Global Assets Advisory LLC purchased a new position in shares of Bristol-Myers Squibb during the 1st quarter worth approximately $5,161,000. Lincoln National Corp increased its holdings in shares of Bristol-Myers Squibb by 7.7% in the first quarter. Lincoln National Corp now owns 42,894 shares of the biopharmaceutical company's stock worth $2,326,000 after purchasing an additional 3,052 shares during the last quarter. Chapin Davis Inc. increased its stake in Bristol-Myers Squibb by 22.6% during the first quarter. Chapin Davis Inc. now owns 22,544 shares of the biopharmaceutical company's stock worth $1,223,000 after acquiring an additional 4,159 shares during the last quarter. Accel Wealth Management increased its stake in Bristol-Myers Squibb by 19.0% during the first quarter. Accel Wealth Management now owns 4,934 shares of the biopharmaceutical company's stock worth $268,000 after acquiring an additional 788 shares during the last quarter. Finally, Brookstone Capital Management boosted its position in shares of Bristol-Myers Squibb by 36.4% during the first quarter. Brookstone Capital Management now owns 150,037 shares of the biopharmaceutical company's stock valued at $8,137,000 after buying an additional 40,018 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Trading Down 2.1 %

Shares of NYSE:BMY traded down $1.11 during midday trading on Monday, hitting $52.11. 5,351,668 shares of the stock were exchanged, compared to its average volume of 14,705,871. The stock has a market capitalization of $105.63 billion, a price-to-earnings ratio of -16.81, a P/E/G ratio of 13.75 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16. The business's 50-day moving average price is $50.46 and its 200 day moving average price is $46.34. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $56.77.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.43. The business had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. Bristol-Myers Squibb's quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.75 EPS. Analysts predict that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.61%. Bristol-Myers Squibb's dividend payout ratio is presently -77.42%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Jefferies Financial Group upped their target price on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a "hold" rating in a report on Wednesday, August 28th. StockNews.com raised shares of Bristol-Myers Squibb from a "buy" rating to a "strong-buy" rating in a research note on Monday, July 29th. Sanford C. Bernstein began coverage on shares of Bristol-Myers Squibb in a research note on Thursday. They issued a "market perform" rating and a $56.00 price target on the stock. BMO Capital Markets reiterated a "market perform" rating and issued a $48.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, September 23rd. Finally, Barclays raised their price target on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an "underweight" rating in a report on Monday, October 7th. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb has an average rating of "Hold" and an average target price of $53.20.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.